JNJ vs NVO: six-factor score, head to head
How Johnson & Johnson and Novo Nordisk A/Scompare on Tapeline’s published six-factor composite score. Descriptive only — a rules-based reading of each name, not a recommendation.
Today, JNJ scores 63 and NVO scores 45on Tapeline’s six-factor composite. JNJ carries the higher composite score today. Here’s how the six factors line up.
| Factor | JNJ | NVO |
|---|---|---|
| Trend | 79 | 39 |
| Relative Strength | 64 | 18 |
| Fundamentals | 80 | 92 |
| Smart Money | 32 | — |
| Macro | 50 | 50 |
| Momentum | 64 | 27 |
fundamentals factor near the top of its range. positive trend factor reading and macro factor on the upper side for the current regime.
relative-strength factor in the bottom band vs the sector. trend factor in the bottom band of its score and fundamentals factor near the top of its range.
The Tapeline Score is a descriptive, rules-based measure for information only — not investment advice or a recommendation to buy or sell. See the six-factor method and the public scorecard.
More comparisons
FAQ
- How do JNJ and NVO compare on Tapeline?
- Tapeline scores JNJ 63/100 and NVO 45/100 on its published six-factor composite score (trend, relative strength, fundamentals, smart money, macro, momentum). The page breaks the two scores down factor by factor.
- Which has the higher Tapeline score, JNJ or NVO?
- JNJ has the higher composite score today (63 vs 45). The score is a descriptive measure, not a recommendation — see the per-factor breakdown above.
- Is this investment advice?
- No. Tapeline publishes a descriptive, rules-based six-factor score for information only. It is not a recommendation to buy or sell, and every top pick is back-checked publicly at /scorecard.